GENOMIC HEALTH INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Net loss
Operating activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization
Employee stock-based compensation
Write-off of previously capitalized software costs
Impairment of long-lived assets
Loss on disposal of property and equipment
Outside director restricted stock awarded in lieu of fees
Gain on sale of equity securities
Discount on convertible promissory note
Discount on equity investment
Unrealized gain on revaluation of equity investment
Unrealized net gain on revaluation of equity investments
Write-off of convertible promissory note
Deferred tax benefit from unrealized gain on available-for-sale marketable securities, net
Changes in assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Accounts payable
Accrued compensation and employee benefits
Accrued expenses and other liabilities
Deferred revenues
Net cash provided by (used in) operating activities
Deferred revenues
Net cash provided by operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Proceeds from sales of marketable securities
Other investments
Net cash used in investing activities
Financing activities
Proceeds from issuance of common stock under stock plans
Withholding taxes related to restricted stock units net share settlement
Net increase (decrease) in cash and cash equivalents
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of period
Cash and cash equivalents at the end of period
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at the beginning of period
Cash, cash equivalents and restricted cash at the end of period
Supplemental disclosure of cash flow information
Cash paid for income taxes
Non-cash investing and financing activities
Accrued purchases of property and equipment
Change in fair value of equity investment
Change in fair value of investments

Comments